Clinical Trials
24
Active:0
Completed:16
Trial Phases
4 Phases
Phase 1:14
Phase 2:4
Phase 3:3
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (24 trials with phase data)• Click on a phase to view related trials
Phase 1
14 (58.3%)Phase 2
4 (16.7%)Not Applicable
3 (12.5%)Phase 3
3 (12.5%)Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.
Not Applicable
Not yet recruiting
- Conditions
- Active Ankylosing Spondylitis
- Interventions
- Drug: VC005 tabletsDrug: VC005 Tablets Placebo
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Target Recruit Count
- 420
- Registration Number
- NCT07172360
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing Municipality, China
Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo
Not Applicable
Not yet recruiting
- Conditions
- Non-segmental Vitiligo
- Interventions
- Drug: VC005 tabletsDrug: VC005 Tablets Placebo
- First Posted Date
- 2025-09-15
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Target Recruit Count
- 120
- Registration Number
- NCT07172347
- Locations
- 🇨🇳
The Peking University People's Hospital, Beijing, Beijng, China
Pharmacokinetic/Pharmacodynamic Study of Vicagrel Capsules and Clopidogrel Tablets in Healthy CYP2C19 Normal Metabolizers
Not Applicable
Completed
- Conditions
- Acute Coronary Syndrome
- Interventions
- First Posted Date
- 2025-07-16
- Last Posted Date
- 2025-09-09
- Lead Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Target Recruit Count
- 18
- Registration Number
- NCT07067775
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
The Mass Balance and Biotransformation Study of [14C] VC005 in Chinese Healthy Adult Male Volunteers
Phase 1
Completed
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: [14C]VC005
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Target Recruit Count
- 6
- Registration Number
- NCT06974292
- Locations
- 🇨🇳
The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China
Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis
Phase 2
Recruiting
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: VC005 groupsDrug: VC005 Placebo group
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Target Recruit Count
- 114
- Registration Number
- NCT06891040
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences Hospital of Skin Disease, Nanjing, Jiangsu, China
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found